Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (51-60 of 134) with videos related to

Pageof 14
Sort By:
International Journal of Dermatology|July 25, 2013
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactionsJonathan L Curry, Carlos A Torres-Cabala, Kevin B Kim, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Cancers|August 10, 2024
Preoperative and Intraoperative Identification of Sentinel Lymph Nodes in Melanoma SurgeryStanley P Leong, Mehdi Nosrati, Max C Wu, et al.
Cancer Investigation|May 15, 2009
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanomaAgop Y Bedikian, Nicholas E Papadopoulos, Kevin B Kim, et al.
Annals of Surgical Oncology|December 4, 2004
A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanomaMatthew T Ballo, Gunar K Zagars, Jeffrey E Gershenwald, et al.
Molecular Cancer Therapeutics|December 7, 2002
Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cellsKevin B Kim, Reuben Lotan, Ping Yue, et al.
Melanoma Research|November 25, 2010
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?Agop Y Bedikian, Marcella M Johnson, Carla L Warneke, et al.
The Journal of Dermatology|March 13, 2014
Case of vemurafenib-induced Sweet's syndromeJeffrey T Yorio, Steven R Mays, Ana M Ciurea, et al.
The Lancet. Oncology|June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyCaroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
Journal of Clinical Pharmacology|October 28, 2010
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver functionAgop Y Bedikian, Jeffrey A Silverman, Nicholas E Papadopoulos, et al.
Pageof 14

Showing results (51-60 of 134) with videos related to

Sort By:
Pageof 14
International Journal of Dermatology|July 25, 2013
Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactionsJonathan L Curry, Carlos A Torres-Cabala, Kevin B Kim, et al.
BMC Cancer|April 18, 2015
Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceJennifer Wheler, Roman Yelensky, Gerald Falchook, et al.
Cancers|August 10, 2024
Preoperative and Intraoperative Identification of Sentinel Lymph Nodes in Melanoma SurgeryStanley P Leong, Mehdi Nosrati, Max C Wu, et al.
Cancer Investigation|May 15, 2009
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanomaAgop Y Bedikian, Nicholas E Papadopoulos, Kevin B Kim, et al.
Annals of Surgical Oncology|December 4, 2004
A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanomaMatthew T Ballo, Gunar K Zagars, Jeffrey E Gershenwald, et al.
Molecular Cancer Therapeutics|December 7, 2002
Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cellsKevin B Kim, Reuben Lotan, Ping Yue, et al.
Melanoma Research|November 25, 2010
Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?Agop Y Bedikian, Marcella M Johnson, Carla L Warneke, et al.
The Journal of Dermatology|March 13, 2014
Case of vemurafenib-induced Sweet's syndromeJeffrey T Yorio, Steven R Mays, Ana M Ciurea, et al.
The Lancet. Oncology|June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyCaroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
Journal of Clinical Pharmacology|October 28, 2010
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver functionAgop Y Bedikian, Jeffrey A Silverman, Nicholas E Papadopoulos, et al.
Pageof 14